Multicenter Uveitis Steroid Treatment (MUST) Trial

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: JHSPH Center for Clinical Trials
• Collaborator: National Eye Institute (NEI)
• Treatments: Alkylating Agents; Azathioprine; Chlorambucil; Cyclophosphamide; Cyclosporine; Cyclosporins; Daclizumab; Fluocinolone Acetonide; Immunosuppressive Agents; Infliximab; Methotrexate; Mycophenolate mofetil; Mycophenolic Acid; Tacrolimus

Criteria

Inclusion Criteria:

• Age 13 years or older

• Best-corrected visual acuity of hand motions or better in at least one eye with uveitis

• Intraocular pressure 24 mm Hg or less in all eyes with uveitis

Exclusion Criteria:

• Inadequately controlled diabetes

• Uncontrolled glaucoma

• Advanced glaucomatous optic nerve injury

• A history of scleritis; presence of an ocular toxoplasmosis scar.

• HIV infection or other immunodeficiency disease for which corticosteroid therapy would be contraindicated according to best medical judgment